Shenfei Zong

Dr. Shenfei Zong


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2019 in Small
Verified
Journal Article
Closed access
PDF file
CCChen Chen
Chen Chen
SZShenfei Zong
Shenfei Zong
YLYun Liu
Yun Liu
ZWZhuyuan Wang
Zhuyuan Wang
YZYizhi Zhang
Yizhi Zhang
YCYiping Cui
Yiping Cui

27 March 2024 in ACS Nano
Verified
Journal Article
Closed access
JWJinxiu Wei
Jinxiu Wei
KZKai Zhu
Kai Zhu
TWTingyu Wang
Tingyu Wang
TQTongsheng Qi
Tongsheng Qi
ZWZhuyuan Wang
Zhuyuan Wang
YCYiping Cui
Yiping Cui

8 November 2016 in Nano Research
Verified
Journal Article
Closed access
PDF file
LWLei Wu
Lei Wu
ZWZhuyuan Wang
Zhuyuan Wang
YZYizhi Zhang
Yizhi Zhang
JFJiayuan Fei
Jiayuan Fei
HCHui Chen
Hui Chen
YCYiping Cui
Yiping Cui
Discovering novel drugs for cancer immunotherapy requires a robust in vitro drug screening platform that allows for straightforward probing of cell–cell communications. Here, we combined surface-enhanced Raman scattering (SERS) nanoprobes with microfluidic networks to monitor in situ the cancer–immune system intercellular communications. The microfluidic platform links up immune cells with cancer cells, where the cancer-cell secretions act as signaling mediators. First, gold@silver core–shell nanorods were employed to fabricate SERS immunoprobes for analysis of the signaling molecules. Multiple cancer secretions in a tumor microenvironment were quantitatively analyzed by a SERS-assisted three-dimensional (3D) barcode immunoassay with high sensitivity (1 ng/mL). Second, in an on-chip cell proliferation assay, multiple immunosuppressive proteins secreted by cancer cells were found to inhibit activation of immune cells, indicating that the platform simulates the physiological process of cancer–immune system communications. Furthermore, potential drug candidates were tested on this platform. A quantitative SERS immunoassay was performed to evaluate drug efficacy at regulating the secretion behavior of cancer cells and the activity of immune cells. This assay showed the suitability of this platform for in vitro drug screening. It is expected that the fully integrated and highly automated SERS-microfluidic platform will become a powerful analytical tool for probing intercellular communications and should accelerate the discovery and clinical validation of novel drugs.

24 June 2025 in ACS Nano
Verified
Journal Article
Closed access
KYKuo Yang
Kuo Yang
QDQianqian Dong
Qianqian Dong
ZYZhibing Yao
Zhibing Yao
JLJingjing Liang
Jingjing Liang
JZJinjin Zhao
Jinjin Zhao
ZWZhuyuan Wang
Zhuyuan Wang

22 April 2023 in TrAC Trends in Analytical Chemistry
Verified
Journal Article
Closed access
JWJinxiu Wei
Jinxiu Wei
TQTongsheng Qi
Tongsheng Qi
CHChenhui Hao
Chenhui Hao
SZShenfei Zong
Shenfei Zong
ZWZhuyuan Wang
Zhuyuan Wang
YCYiping Cui
Yiping Cui

24 October 2014 in RSC Advances
Verified
Journal Article
Closed access
PDF file
DZDan Zhu
Dan Zhu
ZWZhuyuan Wang
Zhuyuan Wang
SZShenfei Zong
Shenfei Zong
HCHui Chen
Hui Chen
PCPeng Chen
Peng Chen
YCYiping Cui
Yiping Cui
A new optical encoding approach, the wavenumber–intensity joint surface enhanced Raman scattering (SERS) spectral encoding method, was demonstrated by using silver nanoparticles with a core–shell structure.